Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05481242
Active, not recruiting Observational

An Observational Study About Adverse Outcomes in Acute Pulmonary Embolism Patients

NCT05481242 · tracked via the Priya Life Science China tracker
Sponsor
Shengjing Hospital
Phase
Observational
Started
2011-01-01
Last updated
2026-03-11

Condition(s) studied

Pulmonary Embolism and ThrombosisDeterioration, Clinical

Investigational drug(s) / intervention(s)

retrospective observational study

retrospective observational study: retrospective observational study

Study summary

This multi-center retrospective study collected clinical, laboratory, and CT pulmonary angiography parameters with acute pulmonary embolism patients from admission to predict adverse outcomes within 30 days after admission into hospital.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * age of ≥ 18 years and a pulmonary embolism diagnosis based on CT pulmonary angiography Exclusion Criteria: * pregnancy * reception of reperfusion treatment before admission * missing data regarding CT parameters, echocardiography, cardiac troponin I (c-Tn I), and N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels.

Primary outcome measure(s)

  • Adverse outcomes — 30 days
    The endpoints of deterioration in this study were defined as the occurrence of any adverse clinical outcomes from medical records and follow-up within 30 days of admission such as death, mechanical ventilation, cardiopulmonary resuscitation, and the need for life-saving vasopressor or reperfusion treatment .In each centre, the researchers for evaluating endpoints were blind to collect and to measure study parameters.

Trial sites (1)

FacilityCityRegionStatus
Shenjing Hospital of CHINA MEDICAL UNIVERSITY Shenyang Liaoning

More Shengjing Hospital trials in China

Psychological Screening and Nursing of Twin Pregnancy Recruiting
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer Recruiting
Axillary Lymph Node Treatment Guided by Naocarbon Tracing After Neoadjuvant Chemotherapy Recruiting
3D MRE-Based Evaluation of Meningioma Mechanical Properties and Histological Features Recruiting
Combined Magnetic Stimulation and Ultrasound for Detrusor Overactivity in SCI Starting soon

Other trials for the same condition

Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography Recruiting
Cognitive Outcomes in BAD-related Stroke Starting soon
A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05481242 on ClinicalTrials.gov ↗ ← All trials in China